Olivier Collard
Overview
Explore the profile of Olivier Collard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
860
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al.
N Engl J Med
. 2024 Sep;
391(9):789-799.
PMID: 39231341
Background: The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma. Methods: We conducted a...
2.
Blay J, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, et al.
Lancet Oncol
. 2024 Aug;
25(9):1163-1175.
PMID: 39127063
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes...
3.
Ray-Coquard I, Savoye A, Schiffler C, Mouret-Reynier M, Derbel O, Kalbacher E, et al.
Nat Commun
. 2024 Jul;
15(1):5931.
PMID: 39013870
This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 ...
4.
Bourien H, Bengrine Lefevre L, Mouret-Reynier M, Asselain B, Lucas B, Gavoille C, et al.
Anticancer Res
. 2023 Jan;
43(2):653-662.
PMID: 36697069
Background/aim: Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following...
5.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al.
Lancet Oncol
. 2022 Jul;
23(8):1044-1054.
PMID: 35835135
Background: Metastatic leiomyosarcomas have a poor prognosis, and currently doxorubicin alone is used as the standard first-line treatment. Doxorubicin combined with trabectedin has shown promising results in phase 1 and...
6.
Fayet Y, Chevreau C, Decanter G, Dalban C, Meeus P, Carrere S, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681600
The national reference network NETSARC+ provides remote access to specialized diagnosis and the Multidisciplinary Tumour Board (MTB) to improve the management and survival of sarcoma patients in France. The IGéAS...
7.
Voute M, Riant T, Amodeo J, Andre G, Barmaki M, Collard O, et al.
Eur J Pain
. 2022 Jan;
26(4):873-887.
PMID: 35092320
Background: There is no recommendation in Europe for the use of ketamine in patients with chronic pain. The heterogeneity of practice highlights the need to seek the advice of experts...
8.
Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298764
Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with...
9.
Callejo A, Faouzi S, Bouche O, Bertucci F, Chevalier T, Isambert N, et al.
Target Oncol
. 2021 Jun;
16(4):485-492.
PMID: 34089444
Background: Retrospective analyses suggest that patients with advanced KIT exon 9-mutated gastrointestinal stromal tumors (GISTs) receiving imatinib 800 mg (rather than 400 mg) daily have better outcomes. In the adjuvant...
10.
Thebault E, Piperno-Neumann S, Tran D, Pacquement H, Marec-Berard P, Lervat C, et al.
Cancers (Basel)
. 2021 Apr;
13(7).
PMID: 33918346
The purpose was to describe first and subsequent relapses in patients from the OS2006/Sarcome-09 trial, to help future trial design. We prospectively collected and analysed relapse data of all French...